Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.
RIVM seeks dialogue with Industry for safe and green chemistry RIVM would like to explore possibilities to eliminate obstacles during innovation of green chemistry with industry.
Biobased alternatives to hormone disrupting substance in cash register receipts Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.
Chikungunya infections in the Caribbean region Since August 2014, there has been an increase in the number of Chikungunya patients in the Caribbean region. Travellers who visit the region can become infected there.
Promising biobased alternatives to substances of very high concern There are many possible biobased alternatives to substances of very high concern (SVHC). Some are even ready to be deployed right away.
Is screening for sexually transmitted infections as part of HIV care cost-effective in the Netherlands? Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.
Regional differences in testing rates underestimate incidence of LGV epidemic Until 2003, Lymphogranuloma venereum (LGV), an aggressive form of chlamydia, was considered to be a rare tropical disease, endemic to Africa, Asia and the Caribbean.